Verona Pharma PLC
VRNA106.910USD
0.0000.00%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
73.55BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Verona Pharma PLC Unternehmen
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Verona Pharma PLC Informationen
BörsenkürzelVRNA
Name des UnternehmensVerona Pharma PLC
IPO-datumMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Anzahl der mitarbeiter209
WertpapierartDepository Receipt
GeschäftsjahresendeMar 30
AddresseRiverside
StadtLONDON
BörseNASDAQ Global Market Consolidated
LandUnited Kingdom
PostleitzahlSE1 2RE
Telefon442032834200
Websitehttps://www.veronapharma.com/
BörsenkürzelVRNA
IPO-datumMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Führungskräfte von Verona Pharma PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Pentwater Capital Management LP
6.15%
HBK Investments, L.P.
4.95%
Fidelity Investments Canada ULC
4.05%
Frazier Life Sciences Management, L.P.
3.93%
Davidson Kempner Capital Management LP
3.80%
Andere
77.14%
Aktionäre
Aktionäre
Anteil
Pentwater Capital Management LP
6.15%
HBK Investments, L.P.
4.95%
Fidelity Investments Canada ULC
4.05%
Frazier Life Sciences Management, L.P.
3.93%
Davidson Kempner Capital Management LP
3.80%
Andere
77.14%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
41.60%
Investment Advisor/Hedge Fund
18.51%
Investment Advisor
11.82%
Research Firm
7.21%
Individual Investor
5.62%
Venture Capital
4.92%
Private Equity
4.03%
Family Office
1.16%
Pension Fund
0.30%
Andere
4.83%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
467
76.61M
88.88%
-7.12M
2025Q2
423
82.86M
96.18%
-3.71M
2025Q1
406
83.91M
98.59%
+940.31K
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Pentwater Capital Management LP
--
0%
+5.30M
-100.00%
HBK Investments, L.P.
--
0%
+4.26M
-100.00%
Fidelity Investments Canada ULC
--
0%
+3.49M
-100.00%
Frazier Life Sciences Management, L.P.
--
0%
--
--
Davidson Kempner Capital Management LP
--
0%
+3.27M
-100.00%
Glazer Capital, LLC
--
0%
+3.21M
-100.00%
Ali (Behbahani)
--
0%
+3.19M
-100.00%
BlackRock Financial Management, Inc.
--
0%
+2.83M
-100.00%
New Enterprise Associates (NEA)
--
0%
-10.14K
-100.00%
Goldman Sachs & Company, Inc.
--
0%
-685.23K
-100.00%
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
iShares Disciplined Volatility Equity Active ETF
0%
AltShares Merger Arbitrage ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Rayliant Quantitative Developed Market Equity ETF
0%
Calvert International Responsible Index ETF
0%
iShares Biotechnology ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
JPMorgan Healthcare Leaders ETF
0%
Global X Guru Index ETF
0%
Mehr Anzeigen
iShares Disciplined Volatility Equity Active ETF
Anteil0%
AltShares Merger Arbitrage ETF
Anteil0%
SPDR Portfolio Developed World ex-US ETF
Anteil0%
Rayliant Quantitative Developed Market Equity ETF
Anteil0%
Calvert International Responsible Index ETF
Anteil0%
iShares Biotechnology ETF
Anteil0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
First Trust IPOX Europe Equity Opportunities ETF
Anteil0%
JPMorgan Healthcare Leaders ETF
Anteil0%
Global X Guru Index ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
